Sign in

CIK 0001501989 · Accelerated filer

CytomX Therapeutics, Inc.

Sign in to watch
Ticker
CTMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273521219
Phone
650.515.3185
Business address
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Chief Medical Officer sold 21,279 shares at $6.42 ($136,675)
  2. 4 Planned sale CEO sold 118,969 shares at $6.42 ($764,138)
  3. 4 Open-market sale SVP, Chief Scientific Officer sold 31,492 shares at $6.42 ($202,273)
  4. 4 Open-market sale Chief Financial Officer sold 19,323 shares at $6.42 ($124,112)
  5. 8-K Event Other events
  6. 424B5 Offering Prospectus
  7. 424B5 Offering Prospectus
  8. S-3ASR Offering Registration Statement
  9. 8-K Event Results of operations
  10. 10-K Report Annual Report
  11. SCHEDULE 13G Stake Statement of Beneficial Ownership
  12. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  13. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  14. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  15. 4 Grant or award Chief Business Officer acquired 20,000 shares (grant or award)
  16. 4 Grant or award Chief Medical Officer acquired 75,000 shares (grant or award)
  17. 4 Grant or award SVP, Chief Scientific Officer acquired 60,000 shares (grant or award)
  18. 4 Grant or award Chief Financial Officer acquired 90,000 shares (grant or award)
  19. 4 Grant or award CEO acquired 210,000 shares (grant or award)
  20. SCHEDULE 13G/A Stake Statement of Beneficial Ownership

Page 3 of 41 · 801 filings